---
schema_version: "secwatch.filing_event.v1"
accession: "0000718937-26-000005"
form_type: "8-K"
ticker: "STAA"
cik: "0000718937"
company_name: "STAAR SURGICAL CO"
filed_at: "2026-03-03T23:59:59+00:00"
generated_at: "2026-05-15T22:24:09.406549+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "low"
source: SEC EDGAR
---

# STAAR Surgical appoints interim co-CEOs; reports China stabilization, EVO+ launch, cost cuts

## Summary
- Warren Foust and Deborah Andrews named Interim Co-CEOs after Alcon merger rejected by shareholders in Jan 2026.
- Cost reductions beat $225M second-half 2025 run rate target; operating expenses lowered significantly.
- China EVO ICL demand recovered at mid-single-digit rate in 2025; distributor inventories normalized.
- EVO+ received China regulatory approval mid-2025; early demand exceeds expectations; shipments began Nov 2025.
- FDA expanded EVO ICL age range to 21-60 in US, adding ~8M potential patients; new SVP hires in supply chain and APAC.

## SEC filing metadata
- accession: 0000718937-26-000005
- form_type: 8-K
- ticker: STAA
- cik: 0000718937
- company_name: STAAR SURGICAL CO
- filed_at: 2026-03-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: low
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/718937/000071893726000005/0000718937-26-000005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/718937/000071893726000005/staa-20260303.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000718937-26-000005
- JSON: https://secwatch.observer/filing/0000718937-26-000005.json
- Plain text: https://secwatch.observer/filing/0000718937-26-000005.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.